TherapeuticsMD Inc (NASDAQ: TXMD) has experienced a decline in its stock price by -16.50 compared to its previous closing price of 1.03. However, the company has seen a fall of -21.46% in its stock price over the last five trading days. benzinga.com reported 2024-08-26 that The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects.
Is It Worth Investing in TherapeuticsMD Inc (NASDAQ: TXMD) Right Now?
The 36-month beta value for TXMD is also noteworthy at 1.16. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for TXMD is 11.34M, and at present, short sellers hold a 0.19% of that float. The average trading volume of TXMD on January 01, 2025 was 20.25K shares.
TXMD’s Market Performance
The stock of TherapeuticsMD Inc (TXMD) has seen a -21.46% decrease in the past week, with a -39.44% drop in the past month, and a -47.56% fall in the past quarter. The volatility ratio for the week is 15.69%, and the volatility levels for the past 30 days are at 8.23% for TXMD. The simple moving average for the past 20 days is -26.28% for TXMD’s stock, with a -50.75% simple moving average for the past 200 days.
TXMD Trading at -36.47% from the 50-Day Moving Average
After a stumble in the market that brought TXMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.73% of loss for the given period.
Volatility was left at 8.23%, however, over the last 30 days, the volatility rate increased by 15.69%, as shares sank -37.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.25% lower at present.
During the last 5 trading sessions, TXMD fell by -21.46%, which changed the moving average for the period of 200-days by -64.17% in comparison to the 20-day moving average, which settled at $1.1665. In addition, TherapeuticsMD Inc saw -61.78% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TXMD starting from Collins Cooper C., who purchase 4,094 shares at the price of $1.73 back on Aug 22 ’24. After this action, Collins Cooper C. now owns 52,016 shares of TherapeuticsMD Inc, valued at $7,099 using the latest closing price.
Collins Cooper C., the Director of TherapeuticsMD Inc, purchase 1,200 shares at $1.70 during a trade that took place back on Aug 21 ’24, which means that Collins Cooper C. is holding 47,922 shares at $2,039 based on the most recent closing price.
Stock Fundamentals for TXMD
Current profitability levels for the company are sitting at:
- -3.79 for the present operating margin
- 0.52 for the gross margin
The net margin for TherapeuticsMD Inc stands at -2.08. The total capital return value is set at -0.18. Equity return is now at value -14.39, with -8.81 for asset returns.
Currently, EBITDA for the company is -8.4 million with net debt to EBITDA at -0.82. When we switch over and look at the enterprise to sales, we see a ratio of 7.69. The receivables turnover for the company is 0.48for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
In summary, TherapeuticsMD Inc (TXMD) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
